Active — Not RecruitingNot Applicable

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

United States, Italy, Spain150 participantsStarted 2021-03-31

Plain-language summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Contraindication or sensitivity to MRI contrast agents
✕. Orthopnea of sufficient severity to preclude supine scanning at screening.
✕. Weight or body girth exceeds the limits of the cardiac MRI machine specifications.
✕. Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.

What they're measuring

Change in the Percent of ECV in Participants Receiving ION-682884 vs. Placebo According to ION-682884-CS2 Treatment Groups

Timeframe: From Baseline up to Week 140

Trial details

NCT IDNCT06073574

SponsorIonis Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03

View on ClinicalTrials.gov More Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) trials